Follow
Pr France Mentre
Pr France Mentre
Pr of Biostatistics, University Paris Diderot
Verified email at inserm.fr - Homepage
Title
Cited by
Cited by
Year
Clinical and virological data of the first cases of COVID-19 in Europe: a case series
FX Lescure, L Bouadma, D Nguyen, M Parisey, PH Wicky, S Behillil, ...
The Lancet Infectious Diseases 20 (6), 697-706, 2020
11162020
Non-linear mixed effects modeling–from methodology and software development to driving implementation in drug development science
GC Pillai, F Mentré, JL Steimer
Journal of pharmacokinetics and pharmacodynamics 32 (2), 161-183, 2005
7842005
Type 1 interferons as a potential treatment against COVID-19
E Sallard, FX Lescure, Y Yazdanpanah, F Mentre, N Peiffer-Smadja
Antiviral research 178, 104791, 2020
5232020
Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea
D Sissoko, C Laouenan, E Folkesson, AB M’lebing, AH Beavogui, S Baize, ...
PLoS medicine 13 (3), e1001967, 2016
5132016
Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R
E Comets, K Brendel, F Mentré
Computer methods and programs in biomedicine 90 (2), 154-166, 2008
4372008
Optimal design in random-effects regression models
F Mentre, A Mallet, D Baccar
Biometrika 84 (2), 429-442, 1997
3861997
Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin
E Maubec, P Petrow, I Scheer-Senyarich, P Duvillard, L Lacroix, J Gelly, ...
J Clin Oncol 29 (25), 3419-3426, 2011
3752011
Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide
K Brendel, E Comets, C Laffont, C Laveille, F Mentré
Pharmaceutical research 23 (9), 2036-2049, 2006
3712006
Hand contamination before and after different hand hygiene techniques: a randomized clinical trial
JC Lucet, MP Rigaud, F Mentre, N Kassis, C Deblangy, A Andremont, ...
Journal of hospital Infection 50 (4), 276-280, 2002
2332002
Model evaluation of continuous data pharmacometric models: metrics and graphics
THT Nguyen, MS Mouksassi, N Holford, N Al‐Huniti, I Freedman, ...
CPT: pharmacometrics & systems pharmacology 6 (2), 87-109, 2017
2222017
Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated?
K Brendel, C Dartois, E Comets, A Lemenuel-Diot, C Laveille, ...
Clinical pharmacokinetics 46 (3), 221-234, 2007
2032007
Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs
S Retout, S Duffull, F Mentré
Computer methods and Programs in Biomedicine 65 (2), 141-151, 2001
1942001
Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model
A Samson, M Lavielle, F Mentré
Computational Statistics & Data Analysis 51 (3), 1562-1574, 2006
1902006
Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software
M Lavielle, F Mentré
Journal of pharmacokinetics and pharmacodynamics 34 (2), 229-249, 2007
1842007
Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques
P Amarenco, S Davis, EF Jones, AA Cohen, WD Heiss, M Kaste, ...
Stroke 45 (5), 1248-1257, 2014
1832014
Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action
C Bazzoli, V Jullien, CL Tiec, E Rey, F Mentré, AM Taburet
Clinical pharmacokinetics 49 (1), 17-45, 2010
1782010
Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics
S Retout, F Mentré
Journal of Biopharmaceutical Statistics 13 (2), 209-227, 2003
1592003
The use of population pharmacokinetics in drug development
S Vozeh, JL Steimer, M Rowland, P Morselli, F Mentré, LP Balant, ...
Clinical pharmacokinetics 30 (2), 81-93, 1996
1571996
Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths
P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ...
Science immunology 6 (62), eabl4340, 2021
1562021
Role of modelling and simulation in Phase I drug development
L Aarons, MO Karlsson, F Mentré, F Rombout, JL Steimer, A van Peer
European journal of pharmaceutical sciences 13 (2), 115-122, 2001
1532001
The system can't perform the operation now. Try again later.
Articles 1–20